Maxvax Biotechnology Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 368

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 17

Maxvax Biotechnology General Information

Description

Developer of innovative human vaccines and novel adjuvants designed for the prevention of infectious diseases and veterinary applications. The company develops recombinant vaccines for shingles and respiratory syncytial virus (RSV) alongside specialized vaccine adjuvants, enabling healthcare providers and veterinary manufacturers to improve immunization efficacy and address unmet medical needs.

Contact Information

Website
www.maxvax.cn
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 2, Number 8, Huigu East Road
  • Shuangliu District
  • Chengdu, Sichuan 610219
  • China
+86 028
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Building 2, Number 8, Huigu East Road
  • Shuangliu District
  • Chengdu, Sichuan 610219
  • China
+86 028

Maxvax Biotechnology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Maxvax Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. IPO 27-May-2026 Announced Clinical Trials - Phase 3
11. Later Stage VC (Series D1) 19-Dec-2025 Completed Clinical Trials - Phase 3
10. Later Stage VC (Series D) 27-Oct-2025 Completed Clinical Trials - Phase 3
9. Secondary Transaction - Private 27-Oct-2025 Completed Clinical Trials - Phase 3
8. Later Stage VC (Series CC) 11-Jun-2024 Completed Clinical Trials - General
7. Later Stage VC (Series C2) 19-Apr-2024 Completed Clinical Trials - General
6. Later Stage VC (Series C) 21-Feb-2024 Completed Clinical Trials - General
5. Later Stage VC (Series B1) 05-Dec-2022 Completed Clinical Trials - General
4. Later Stage VC (Series B) 20-Jul-2022 $74.4M $88.7M Completed Clinical Trials - General
3. Later Stage VC (Series A) 21-Jul-2021 $14.2M Completed Clinical Trials - General
To view Maxvax Biotechnology’s complete valuation and funding history, request access »

Maxvax Biotechnology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 2,851,533 $16.36 $16.36 1x $16.36 7.37%
Ordinary 2,812,648 $15.58 $15.58 1x $15.58 7.27%
To view Maxvax Biotechnology’s complete cap table history, request access »

Maxvax Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of innovative human vaccines and novel adjuvants designed for the prevention of infectious diseases and veteri
Drug Discovery
Chengdu, China
368 As of 2025

Guangzhou, China
 

Suzhou, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Maxvax Biotechnology Competitors (3)

One of Maxvax Biotechnology’s 3 competitors is MingMed Biotech, a Venture Capital-Backed company based in Guangzhou, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MingMed Biotech Venture Capital-Backed Guangzhou, China
AbogenBio Venture Capital-Backed Suzhou, China
Acon Biotech Corporation Hangzhou, China
You’re viewing 3 of 3 competitors. Get the full list »

Maxvax Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Maxvax Biotechnology Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Chengdu Bio-Town Investment Government Minority
Chengdu Technology Transfer Venture Corporate Venture Capital Minority
Shanghai Lingang Economic Development Limited Partner Minority
Hankang Capital Growth/Expansion Minority
IDG Capital Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Maxvax Biotechnology FAQs

  • When was Maxvax Biotechnology founded?

    Maxvax Biotechnology was founded in 2016.

  • Where is Maxvax Biotechnology headquartered?

    Maxvax Biotechnology is headquartered in Chengdu, China.

  • What is the size of Maxvax Biotechnology?

    Maxvax Biotechnology has 368 total employees.

  • What industry is Maxvax Biotechnology in?

    Maxvax Biotechnology’s primary industry is Drug Discovery.

  • Is Maxvax Biotechnology a private or public company?

    Maxvax Biotechnology is a Private company.

  • What is Maxvax Biotechnology’s current revenue?

    The current revenue for Maxvax Biotechnology is .

  • How much funding has Maxvax Biotechnology raised over time?

    Maxvax Biotechnology has raised $260M.

  • Who are Maxvax Biotechnology’s investors?

    Chengdu Bio-Town Investment, Chengdu Technology Transfer Venture, Shanghai Lingang Economic Development, Hankang Capital, and IDG Capital are 5 of 17 investors who have invested in Maxvax Biotechnology.

  • Who are Maxvax Biotechnology’s competitors?

    MingMed Biotech, AbogenBio, and Acon Biotech are competitors of Maxvax Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process